Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07219953 | A Study of Brenipatide in Participants With Alcohol Use Disorder | PHASE3 | RECRUITING | 1,100 | — | — | Oct 16, 2025 | Apr 1, 2028 | Jun 3, 2026 | 119 | United States, Belgium +6 |
| NCT07219966 | A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder | PHASE3 | RECRUITING | 1,100 | — | — | Oct 15, 2025 | Apr 1, 2028 | Jun 3, 2026 | 123 | United States, Belgium +6 |
| Arm | Type | Description |
|---|---|---|
| LY3537031 Period 1 | EXPERIMENTAL | Escalating doses administered subcutaneously (SC) |
| LY3537031 Period 2 | EXPERIMENTAL | Administered SC |
| Placebo | PLACEBO_COMPARATOR | Administered SC |
| Name | Type | Description |
|---|---|---|
| LY3537031 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Participant must be a minimum of 20 years of age for the investigative sites in Japan. * Are seeking treatment and are motivated to stop or cut down on drinking. * Are reliable and willing to make themselves available for the duration of the study and attend required study vis...